For the interim period of the fiscal year ending March 2027, Tsubota Laboratory Incorporated reported revenue of 4.41 hundred million yen (YoY +3.39 hundred million yen), operating loss of -295 million yen, ordinary loss of -259 million yen, and interim net loss of -260 million yen. The company aims to return to profitability in the second half through milestone payments under existing contracts and new licensing agreements. Consolidation of Mediproduce as a subsidiary strengthens the business base. Full-year guidance for the current fiscal year anticipates revenue of 1,400\u20131,800 million yen, operating profit of 0\u201345 million yen, ordinary profit of 40\u201385 million yen, and net profit of 40\u201385 million yen (including 9 months). Major pipeline progress includes clinical advancement of TLM-001\/TLM-003 and preparations for China expansion and additional trials for TLG-001\/TLG-003. The company plans to secure funding via stock options up to approximately 2,000 million yen to be allocated to clinical development, licensing-in, and new businesses.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4890","jir_company_name":"Tsubota Laboratory Incorporated","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4890-20261111-02.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, Tsubota Laboratory Incorporated reported revenue of 4.41 hundred million yen (YoY +3.39 hundred million yen), operating loss of -295 million yen, ordinary loss of -259 million yen, and interim net loss of -260 million yen. The company aims to return to profitability in the second half through milestone payments under existing contracts and new licensing agreements. Consolidation of Mediproduce as a subsidiary strengthens the business base. Full-year guidance for the current fiscal year anticipates revenue of 1,400\u20131,800 million yen, operating profit of 0\u201345 million yen, ordinary profit of 40\u201385 million yen, and net profit of 40\u201385 million yen (including 9 months). Major pipeline progress includes clinical advancement of TLM-001\/TLM-003 and preparations for China expansion and additional trials for TLG-001\/TLG-003. The company plans to secure funding via stock options up to approximately 2,000 million yen to be allocated to clinical development, licensing-in, and new businesses.","jir_summary":"### Overview of Performance\nFor the interim period, Tsubota Laboratory Incorporated reported standalone revenue of 4.41 hundred million yen, driven by a recovery in license revenues. However, the company recorded an operating loss of -295 million yen, and ordinary and interim net losses continued. The consolidation of Mediproduce as a subsidiary has diversified the revenue structure and strengthened the business base. The company aims to achieve full-year profitability in the second half through milestone payments from existing contracts and progress in new licensing agreements. R&D expenditure will continue to be invested.\n\n### Outlook and Funding\nAs of the end of September, cash and equivalents stood at 11.86 hundred million yen. The company has an overdraft facility of 1,000 million yen and has set stock options up to approximately 2,000 million yen. The second-half outlook assumes consolidated revenue (Tsubota Laboratory Incorporated plus Mediproduce) of 1,400\u20131,800 million yen, operating income of 0\u201345 million yen, ordinary income of 40\u201385 million yen, and interim net income of 40\u201385 million yen. Funds will be allocated to clinical development, licensing-in activities, and new business initiatives.","jir_financial_highlights":"Tsubota Laboratory Incorporated standalone revenue: 4.41 (YoY +3.39)\nOperating Income: -295 (Prior period -351 -> Current -295)\nOrdinary Income: -259 (Prior period -333 -> Current -259)\nInterim Net Income: -260 (Prior period -333 -> Current -260)\nCash and Cash Equivalents: 11.86 (End of prior period 9.69 -> Current 11.86)\nOutstanding Borrowings: 3.96 (Change from prior period end unknown)","jir_category":"","jir_hashtags":"#TsubotaLaboratory, #InterimResults, #LicenseRevenue, #SubsidiaryConsolidation","jir_key_figures":"Revenue (interim): 4.41 hundred million yen\nInterim Net Income: -2.60 hundred million yen\nCash and Cash Equivalents: 11.86 hundred million yen","jir_meta_title":"Tsubota Laboratory Incorporated \u2014 Key Points of Interim Results for FY2027 | November 11","jir_meta_description":"Summary of Tsubota Laboratory Incorporated's interim results for FY2027: revenue of 4.41 hundred million yen, trends in losses, second-half path to profitability, impact of Mediproduce consolidation, and planned use of funding facilities.","jir_og_title":"Tsubota Laboratory Incorporated Interim Results Summary | 2026-11-11","jir_og_description":"Tsubota Laboratory Incorporated reported interim revenue of 4.41 hundred million yen with continued losses. The company aims for second-half profitability using subsidiary consolidation and available funding facilities.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-3\\\",\\\"2026-3\\\",\\\"2027-3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[486,441,1100]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-3\\\",\\\"2026-3\\\",\\\"2027-3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[69,-295,5]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Interim Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-3\\\",\\\"2026-3\\\",\\\"2027-3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Interim Net Income\\\",\\\"data\\\":[44,-260,45]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"cash_balance_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Cash Balance Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-3\\\",\\\"2026-3\\\",\\\"2026-9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Cash and Cash Equivalents\\\",\\\"data\\\":[9.69,11.86,11.86]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"debt_balance_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Borrowings Balance Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-3\\\",\\\"2026-9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Outstanding Borrowings\\\",\\\"data\\\":[0,3.96]}]},\\\"options\\\":{}}\"}]","ir_related_company":122803,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149196","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n